Literature DB >> 18187073

Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study.

Michael G Shlipak1, Joachim H Ix, Kirsten Bibbins-Domingo, Feng Lin, Mary A Whooley.   

Abstract

PURPOSE: The study purpose was to evaluate the ability of 6 biomarkers to improve the prediction of cardiovascular events among persons with established coronary artery disease.
BACKGROUND: Cardiovascular risk algorithms are designed to predict the initial onset of coronary artery disease but are less effective in persons with preexisting coronary artery disease.
METHODS: We examined the association of N-terminal prohormone brain natriuretic peptide (Nt-proBNP), cystatin C, albuminuria, C-reactive protein (CRP), interleukin-6, and fibrinogen with cardiovascular events in 979 Heart and Soul Study participants with coronary artery disease after adjusting for demographic, lifestyle, and behavior variables; cardiovascular risk factors; cardiovascular disease severity; medication use; and left ventricular ejection fraction. The outcome was a composite of stroke, myocardial infarction, and coronary heart disease death during an average of 3.5 years of follow-up.
RESULTS: During follow-up, 142 participants (15%) developed cardiovascular events. The highest quartiles (vs lower 3 quartiles) of 5 biomarkers were individually associated with cardiovascular risk after multivariate analysis: Nt-proBNP hazard ratio (HR)=2.13 (95% confidence interval [CI], 1.43-3.18); cystatin C HR=1.72 (95% CI, 1.10-2.70); albuminuria HR=1.71 (95% CI, 1.15-2.54); CRP HR=2.00 (95% CI, 1.40-2.85); and interleukin-6 HR=1.76 (95% CI, 1.22-2.53). When all biomarkers were included in the multivariable analysis, only Nt-proBNP, albuminuria, and CRP remained significant predictors of events: HR=1.88 (95% CI, 1.23-2.85), HR=1.63 (95% CI, 1.09-2.43), and HR=1.82 (95% CI, 1.24-2.67), respectively. The area under the receiver operator curve for clinical predictors alone was 0.73 (95% CI, 0.68-0.78); adding Nt-proBNP, albuminuria, and CRP significantly increased the area under the receiver operator curve to 0.77 (95% CI, 0.73-0.82, P<.005).
CONCLUSION: Among persons with prevalent coronary artery disease, biomarkers reflecting hemodynamic stress, kidney damage, and inflammation added significant risk discrimination for cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187073      PMCID: PMC2239343          DOI: 10.1016/j.amjmed.2007.06.030

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  17 in total

1.  Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.

Authors:  Stefan Blankenberg; Matthew J McQueen; Marek Smieja; Janice Pogue; Cynthia Balion; Eva Lonn; Hans J Rupprecht; Christoph Bickel; Laurence Tiret; Francois Cambien; Hertzel Gerstein; Thomas Münzel; Salim Yusuf
Journal:  Circulation       Date:  2006-07-10       Impact factor: 29.690

2.  N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease.

Authors:  Kirsten Bibbins-Domingo; Reena Gupta; Beeya Na; Alan H B Wu; Nelson B Schiller; Mary A Whooley
Journal:  JAMA       Date:  2007-01-10       Impact factor: 56.272

3.  Fetuin-A and kidney function in persons with coronary artery disease--data from the Heart and Soul Study.

Authors:  Joachim H Ix; Glenn M Chertow; Michael G Shlipak; Vincent M Brandenburg; Markus Ketteler; Mary A Whooley
Journal:  Nephrol Dial Transplant       Date:  2006-04-27       Impact factor: 5.992

4.  Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study.

Authors:  Joachim H Ix; Michael G Shlipak; Glenn M Chertow; Mary A Whooley
Journal:  Circulation       Date:  2006-12-26       Impact factor: 29.690

5.  Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women.

Authors:  B G Angeja; M G Shlipak; A S Go; S C Johnston; P D Frederick; J G Canto; H V Barron; D Grady
Journal:  J Am Coll Cardiol       Date:  2001-11-01       Impact factor: 24.094

6.  Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide.

Authors:  Marc S Sabatine; David A Morrow; James A de Lemos; C Michael Gibson; Sabina A Murphy; Nader Rifai; Carolyn McCabe; Elliott M Antman; Christopher P Cannon; Eugene Braunwald
Journal:  Circulation       Date:  2002-04-16       Impact factor: 29.690

7.  Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease.

Authors:  Dietrich Rothenbacher; Wolfgang Koenig; Hermann Brenner
Journal:  Arch Intern Med       Date:  2006 Dec 11-25

8.  C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study.

Authors:  Mary S Beattie; Michael G Shlipak; Haiying Liu; Warren S Browner; Nelson B Schiller; Mary A Whooley
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

9.  Depressive symptoms and health-related quality of life: the Heart and Soul Study.

Authors:  Bernice Ruo; John S Rumsfeld; Mark A Hlatky; Haiying Liu; Warren S Browner; Mary A Whooley
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

10.  Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study.

Authors:  Eric Vittinghoff; Michael G Shlipak; Paul D Varosy; Curt D Furberg; Christine C Ireland; Steven S Khan; Roger Blumenthal; Elizabeth Barrett-Connor; Stephen Hulley
Journal:  Ann Intern Med       Date:  2003-01-21       Impact factor: 25.391

View more
  36 in total

1.  Cystatin C is associated with inflammation but not atherosclerosis in systemic lupus erythematosus.

Authors:  R Lertnawapan; A Bian; Y H Rho; P Raggi; A Oeser; J F Solus; T Gebretsadik; A Shintani; C M Stein
Journal:  Lupus       Date:  2011-11-09       Impact factor: 2.911

2.  The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease.

Authors:  Naja Dam Mygind; Marina J Harutyunyan; Anders Bruun Mathiasen; Rasmus S Ripa; Jens Jacob Thune; Jens Peter Gøtze; Julia S Johansen; Jens Kastrup
Journal:  Inflamm Res       Date:  2010-10-23       Impact factor: 4.575

3.  Elevated Levels of Serum Fibrin and Fibrinogen Degradation Products Are Independent Predictors of Larger Coronary Plaques and Greater Plaque Necrotic Core.

Authors:  Michel T Corban; Olivia Y Hung; Girum Mekonnen; Parham Eshtehardi; Danny J Eapen; Emad Rasoul-Arzrumly; Hatem Al Kassem; Pankaj Manocha; Yi-An Ko; Laurence S Sperling; Arshed A Quyyumi; Habib Samady
Journal:  Circ J       Date:  2016-02-25       Impact factor: 2.993

4.  The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects.

Authors:  Paul M McKie; Alessandro Cataliotti; Brian D Lahr; Fernando L Martin; Margaret M Redfield; Kent R Bailey; Richard J Rodeheffer; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2010-05-11       Impact factor: 24.094

Review 5.  Biomarkers of atherosclerosis: clinical applications.

Authors:  Todd M Brown; Vera Bittner
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

6.  Psychological risk factors and the metabolic syndrome in patients with coronary heart disease: findings from the Heart and Soul Study.

Authors:  Beth E Cohen; Praveen Panguluri; Beeya Na; Mary A Whooley
Journal:  Psychiatry Res       Date:  2009-12-06       Impact factor: 3.222

7.  Interruption of antiretroviral therapy is associated with increased plasma cystatin C.

Authors:  Amanda Mocroft; Christina Wyatt; Lynda Szczech; Jacquie Neuhaus; Wafaa El-Sadr; Russell Tracy; Lewis Kuller; Michael Shlipak; Brian Angus; Harting Klinker; Michael Ross
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

8.  The influence of cardiac rehabilitation on inflammation and metabolic syndrome in women with coronary heart disease.

Authors:  Theresa M Beckie; Jason W Beckstead; Maureen W Groer
Journal:  J Cardiovasc Nurs       Date:  2010 Jan-Feb       Impact factor: 2.083

Review 9.  Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story.

Authors:  Roberto Ferrari; Kim Fox
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  Factors contributing to hospitalization for gastroparesis exacerbations.

Authors:  Sesha S Uppalapati; Zeeshan Ramzan; Robert S Fisher; Henry P Parkman
Journal:  Dig Dis Sci       Date:  2009-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.